Johnson & Johnson JNJ Business Segments
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| Sales to customers (Note 9) by Business | |||||
| Innovative Medicine | $60.4B+6.0% | $56.96B+4.0% | $54.76B+4.2% | $52.56B+1.7% | |
| MEDTECH | $33.79B+6.1% | $31.86B+4.8% | $30.4B+10.8% | $27.43B+1.4% | |
| Other (income) expense, net by Business | |||||
| Innovative Medicine | -$713M-67.4% | -$426M-143% | $993M-33.5% | $1.49B— | |
| MEDTECH | $938M+265% | $257M+144% | -$589M-207% | $553M— | |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest by Business | |||||
| Innovative Medicine | $22.27B+17.7% | $18.92B+3.7% | $18.25B+16.6% | $15.65B-11.8% | |
| MEDTECH | $4.11B+10.0% | $3.74B-19.9% | $4.67B+5.0% | $4.45B+5.7% | |
| Total Assets by Business | |||||
| General Corporate | $147.55B— | —— | —— | —— | |
| Innovative Medicine | $286.69B— | —— | —— | —— | |
| MEDTECH | $344.84B— | —— | —— | —— | |
| Cost of products sold by Business | |||||
| Innovative Medicine | $15.65B+11.5% | $14.04B+2.3% | $13.72B-2.5% | $14.07B— | |
| MEDTECH | $14.55B+9.0% | $13.35B+4.9% | $12.72B+22.4% | $10.4B— | |
| Depreciation and Amortization by Business | |||||
| Consumer Health | $0— | $0-100% | $383M-40.2% | $641M-13.3% | |
| General Corporate | $241M-29.5% | $342M+9.3% | $313M-7.9% | $340M+1.2% | |
| Innovative Medicine | $3.77B+0.3% | $3.76B-2.3% | $3.85B+4.3% | $3.69B-8.5% | |
| MEDTECH | $3.49B+7.8% | $3.24B+10.0% | $2.94B+27.8% | $2.3B+0.7% | |
| Selling, marketing and administrative expenses by Business | |||||
| Innovative Medicine | $11.38B+4.3% | $10.91B+10.8% | $9.84B+1.3% | $9.71B— | |
| MEDTECH | $11.35B+5.0% | $10.81B+3.2% | $10.48B+9.8% | $9.54B— | |
| Research and development expense by Business | |||||
| Innovative Medicine | $11.83B-12.6% | $13.53B+13.1% | $11.96B+2.8% | $11.64B— | |
| MEDTECH | $2.84B-23.4% | $3.7B+18.6% | $3.12B+25.2% | $2.49B— | |
| Additions to Property, Plant & Equipment by Business | |||||
| Consumer Health | $0— | $0-100% | $162M-46.5% | $303M-3.5% | |
| General Corporate | $255M-5.9% | $271M-23.9% | $356M+67.9% | $212M+2.4% | |
| Innovative Medicine | $2.08B+21.4% | $1.71B+3.4% | $1.65B+20.3% | $1.37B+14.7% | |
| MEDTECH | $2.5B+2.4% | $2.44B+3.0% | $2.37B+11.9% | $2.12B+9.7% | |
| Goodwill, Written off Related to Sale of Business Unit by Business | |||||
| Innovative Medicine | $0— | $0— | —— | $0— | |
| Percent Change (as a percent) by Business | |||||
| Innovative Medicine | 68.5%+91.6pp | -23.1%— | —— | 9.9%— | |
| Restructuring by Business | |||||
| Medtech Ortho Franchise | $152M+15.2% | $132M-52.7% | $279M— | —— | |
| Orthopaedics Restructuring Plan | $307M— | —— | —— | —— | |
| Goodwill (Note 3) by Business | |||||
| Innovative Medicine | $54.47B+26.3% | $43.12B+4.7% | $41.19B+2.2% | $40.29B-6.0% | |
| MEDTECH | $134.94B+6.5% | $126.74B+21.6% | $104.2B+47.4% | $70.71B+18.7% | |
| Currency translation/Other by Business | |||||
| Innovative Medicine | $815M+330% | -$355M-259% | $223M— | —— | |
| MEDTECH | $337M+316% | -$156M— | —— | —— | |
| Goodwill, related to acquisitions by Business | |||||
| Innovative Medicine | $3.52B+450% | $640M— | $0— | $0— | |
| MEDTECH | $0-100% | $7.57B— | $0-100% | $11.06B— | |
| Sales to customers (Note 9) by Product | |||||
| ADVANCED | $4.58B+2.0% | $4.49B-3.9% | $4.67B+2.2% | $4.57B-1.1% | |
| CAPLYTA | $700M— | $0— | $0— | —— | |
| CARVYKTI | $1.89B+96.0% | $963M+92.6% | $500M+276% | $133M— | |
| CONCERTA/Methylphenidate | $584M-8.9% | $641M-18.1% | $783M+21.6% | $644M-3.4% | |
| CONTACT LENSES / OTHER | $3.91B+4.7% | $3.73B+0.8% | $3.7B+4.5% | $3.54B+3.0% | |
| DARZALEX | $14.35B+23.0% | $11.67B+19.8% | $9.74B+22.2% | $7.98B+32.4% | |
| EDURANT/rilpivirine | $1.49B+16.8% | $1.27B+10.6% | $1.15B+14.1% | $1.01B+1.4% | |
| ERLEADA | $3.57B+19.2% | $3B+25.6% | $2.39B+26.9% | $1.88B+45.7% | |
| GENERAL | $5.56B+3.8% | $5.36B-0.1% | $5.37B+4.8% | $5.12B-1.3% | |
| HIPS | $1.67B+2.2% | $1.64B+5.0% | $1.56B+3.0% | $1.51B+2.3% | |
| IMBRUVICA | $2.82B-7.1% | $3.04B-6.9% | $3.26B-13.8% | $3.79B-13.4% | |
| INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA | $3.81B-9.8% | $4.22B+2.6% | $4.12B-0.6% | $4.14B+3.0% | |
| KNEES | $1.59B+2.7% | $1.55B+6.1% | $1.46B+7.1% | $1.36B+2.6% | |
| OTHER IMMUNOLOGY | $61M+1,933% | $3M-72.7% | $11M-35.3% | $17M-29.2% | |
| OTHER INFECTIOUS DISEASES | $175M-57.5% | $412M-70.9% | $1.41B+345% | $318M-12.4% | |
| OTHER NEUROSCIENCE | $1.05B-10.8% | $1.18B-24.3% | $1.55B-10.4% | $1.73B-16.4% | |
| Other Oncology | $501M+58.0% | $317M-5.7% | $336M-20.6% | $423M-25.5% | |
| Other | $3.66B+208% | $1.19B-9.0% | $1.31B-7.6% | $1.41B-15.9% | |
| PREZISTA/PREZCOBIX/REZOLSTA/SYMTUZA | $1.58B-7.8% | $1.71B-7.7% | $1.85B-4.6% | $1.94B-6.7% | |
| Remicade | $1.77B+10.2% | $1.61B-12.7% | $1.84B-21.5% | $2.34B-26.6% | |
| RYBREVANT + LAZCLUZE | $734M+124% | $327M+252% | $93M— | —— | |
| SIMPONI / SIMPONI ARIA | $2.67B+21.8% | $2.19B-0.3% | $2.2B+0.6% | $2.18B-4.0% | |
| SPRAVATO | $1.7B+57.5% | $1.08B+56.3% | $689M+84.2% | $374M— | |
| STELARA | $6.08B-41.3% | $10.36B-4.6% | $10.86B+11.7% | $9.72B+6.4% | |
| SURGICAL | $1.56B+10.3% | $1.41B+3.1% | $1.37B+4.9% | $1.31B+4.6% | |
| TALVEY | $463M+61.3% | $287M+356% | $63M— | —— | |
| Tecvayli | $670M+22.0% | $549M+39.0% | $395M+2,533% | $15M— | |
| TRAUMA | $3.15B+3.2% | $3.05B+2.3% | $2.98B+3.8% | $2.87B-0.5% | |
| Tremfya | $5.16B+40.5% | $3.67B+16.6% | $3.15B+18.0% | $2.67B+25.4% | |
| UPTRAVI | $1.9B+4.7% | $1.82B+14.9% | $1.58B+19.7% | $1.32B+6.9% | |
| XARELTO | $2.63B+11.0% | $2.37B+0.3% | $2.37B-4.4% | $2.47B+1.4% | |
| Percent Change (as a percent) by Product | |||||
| ADVANCED | 5.9%— | —— | 4.7%+4.0pp | 0.7%— | |
| CAPLYTA | 0%— | 0%— | —— | —— | |
| CONCERTA/Methylphenidate | -20.2%— | —— | —— | -8.2%-24.2pp | |
| CONTACT LENSES / OTHER | 12.3%+13.2pp | -0.9%-13.4pp | 12.5%— | —— | |
| DARZALEX | 66.3%+7.8pp | 58.5%-7.8pp | 66.3%— | —— | |
| EDURANT/rilpivirine | 49.5%— | —— | —— | -10.1%— | |
| ERLEADA | 54.9%— | —— | —— | —— | |
| GENERAL | 8.2%+8.5pp | -0.3%-13.2pp | 12.9%+15.1pp | -2.2%— | |
| HIPS | 5.1%— | —— | 9.2%— | —— | |
| KNEES | 4.9%— | —— | 20%+12.7pp | 7.3%— | |
| Other Oncology | 47.6%-44.8pp | 92.4%— | —— | -21.5%+71.3pp | |
| SPRAVATO | 161.1%— | —— | —— | —— | |
| STELARA | -119.5%-113pp | -6.6%-39.1pp | 32.5%— | —— | |
| SURGICAL | 29.3%+25.3pp | 4%— | —— | —— | |
| TALVEY | 170.2%— | —— | —— | —— | |
| TRAUMA | 7.4%+0.8pp | 6.6%-4.5pp | 11.1%+11.4pp | -0.3%— | |
| Tremfya | 100%— | —— | 50%— | —— | |
| UPTRAVI | 14.1%— | —— | 55.6%+35.9pp | 19.7%— | |
| Sales to Customers by Product | |||||
| ELECTROPHYSIOLOGY | $5.63B+7.0% | $5.27B+12.4% | $4.69B+19.1% | $3.94B+8.7% | |
| other cardiovascular | $397M+4.5% | $380M+6.7% | $356M+7.2% | $332M— | |
| SPINE,SPORTS & OTHER | $2.85B-2.5% | $2.93B-0.7% | $2.95B+3.7% | $2.84B-1.9% | |
| % Change by Product | |||||
| ELECTROPHYSIOLOGY | 7%-5.3pp | 12.3%-6.8pp | 19.1%+10.4pp | 8.7%— | |
| other cardiovascular | 4.3%-2.6pp | 6.9%-0.2pp | 7.1%— | —— | |
| SPINE,SPORTS & OTHER | -2.5%-1.8pp | -0.7%-4.4pp | 3.7%+5.6pp | -1.9%-9.3pp | |
| Sales to customers (Note 9) by Geography | |||||
| Asia-Pacific, Africa | $14.03B+3.2% | $13.59B-1.2% | $13.76B-8.2% | $14.98B+10.3% | |
| Europe | $21.54B+6.5% | $20.21B-1.0% | $20.41B-7.6% | $22.08B+7.2% | |
| United States | $53.75B+6.9% | $50.3B+8.3% | $46.44B+2.7% | $45.23B+11.3% | |
| Western Hemisphere, excluding U.S. | $4.88B+3.4% | $4.71B+3.6% | $4.55B-10.8% | $5.1B+18.9% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Johnson & Johnson break its business down?
- Johnson & Johnson (JNJ) reports sales to customers (note 9) by business across 2 parts — Innovative Medicine and MEDTECH. Each is extracted from the segment footnotes and tracked over time.
- Where does Johnson & Johnson's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Johnson & Johnson's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
